ISSN: 2306-6091

International Journal of Pharmaceuticals and Health Care Research (IJPHR)

IJPHR |Vol.14 | Issue 3 | Jul - Sep -2026

www.ijphr.com

DOI : https://doi.org/10.61096/ijphr.v14.iss3.2026.537.543

Medical Imaging in Drug Development Applications, Challenges, Future Directions

***Pratti Divya Sri [1], Chitla Sireesha[1], Santhosh kumar[1], Vemavarapu Sathish Kumar[2]**

[1] *Intern, Clinoxy Solutions Pvt., Ltd., Hyderabad. Telangana.*

[2]*Founder, Clinoxy Solutions Pvt., Ltd., Hyderabad. Telangana.*

Author for Correspondence: ***Pratti Divya Sri**
Email: prattidivyasripratti@gmail.com

Published on: 17.08.2026
Published by: Futuristic Publications

Abstract: Medical imaging is now considered a critical tool in drug development by providing valuable information throughout the clinical research process. It enables researchers to evaluate disease progressions, identify suitable patient populations, detect and characterize lesions, assessment of disease severity, monitor treatment response over time. These capabilities improve decision -making during clinical trials and contribute to the development of safer and more effective therapies. Advanced imaging techniques, including Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and ultrasound, offer detailed insights into drug pharmacokinetics, biodistribution, and biological activity. Molecular imaging approaches also allow investigators to visualize specific cellular and biochemical processes, supporting the assessment of drug mechanisms and therapeutic targets. Imaging biomarkers and surrogate imaging endpoints have gained significant importance in evaluating drug efficacy. Compared with conventional clinical endpoints, they often provide earlier, more objective, and highly reproducible measurements of treatment effects. As a result, imaging can reduce clinical trial duration, and improve statistical reliability. Furthermore, medical imaging plays a crucial role in monitoring drug safety, especially in situations where other biomarkers are unavailable or insufficient. Although radiology has a long history, the use of medical imaging in drug development has expanded rapidly in recent years. This article discusses the applications, advantages, challenges, and future prospects of medical imaging in the development of drugs.

Keyword: Drug development, medical imaging, Clinical trials, Diagnostic radiology, Imaging biomarkers, pharmaceutical research, PET, MRI, Drug safety.

Introduction:

The development of a new drug is a complex, lengthy, and highly regulated process that typically takes 10-15 years from initial discovery to regulatory approval. During this period, thousands of potential compounds are screened in preclinical studies, but only a small number progress to human clinical trials, and even fewer ultimately receive approval from regulatory authorities. Because of this high failure rate, obtaining reliable information on a drug's safety, efficacy, pharmacokinetics, and mechanism of action during the early stages of clinical development is essential to improve decision-making and reduce late-stage trial failures.

Medical imaging has emerged as a powerful tool in modern drug development, providing non-invasive methods to assess disease characteristics, monitor therapeutic response, and evaluate drug effects in both preclinical and clinical settings. Advances in imaging technologies, combined with the increasing focus on chronic and complex diseases, have expanded the role of imaging in pharmaceutical research. Imaging techniques help identify patients who are most likely to benefit from a treatment, detect and characterize disease lesions, determine disease severity, and monitor treatment outcomes throughout clinical trials.

Preclinical imaging using animal disease models also plays an important role in translational research by identifying novel imaging biomarkers and correlating imaging findings with histopathological changes. These approaches improve the understanding of disease mechanisms and facilitate the successful translation of research findings from laboratory studies to human clinical trials. Furthermore, imaging biomarkers provide objective and quantitative measures that support the evaluation of drug efficacy and safety while enhancing the efficiency and reliability of clinical studies. This article provides an overview of the drug development process and discusses the growing importance of medical imaging in clinical research. It also highlights the principles of designing imaging-based clinical trials and explores the applications, advantages, and future potential of medical imaging in therapeutic drug development. Although the primary focus is on therapeutic clinical trials, many of the concepts discussed are also applicable to the development of imaging contrast agents and radiopharmaceuticals.

2. Overview of Drug Development

Drug development begins with target identification and lead compound optimization, followed by preclinical studies to evaluate pharmacological activity and toxicity in laboratory and animal models. Compounds that demonstrate acceptable safety profiles proceed to human clinical trials, which are conducted in sequential phases before regulatory approval.

2.1 Preclinical Development

Preclinical studies evaluate the pharmacological effects, toxicity, pharmacokinetics, and pharmacodynamics of potential drug candidates. Medical imaging techniques are increasingly incorporated during this stage to monitor disease progression, assess treatment response, and identify imaging biomarkers that can be translated into clinical research.

2.2 Phase 1 Clinical Trials

Phase 1 trials primarily assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a new drug in healthy volunteers or selected patients. Imaging techniques may be used to evaluate drug distribution, receptor binding, and early biological effects.

2.3 Phase 2 Clinical Trials

Phase 2 studies investigate the preliminary efficacy of the drug while continuing safety assessment. Imaging biomarkers assist in identifying treatment responders, determining optimal dosage, and monitoring disease progression.

2.4 Phase 3 Clinical Trials

Phase 3 trials involve large patient populations to confirm efficacy and safety compared with standard treatment or placebo. Medical imaging provides objective evidence of therapeutic response and supports clinical endpoint evaluation.

2.5 Phase 4 (Post-Marketing Surveillance)

After regulatory approval, phase 4 studies monitor long-term safety, effectiveness, and rare adverse events in the general population. Imaging continues to play a role in evaluating long-term treatment outcomes and identifying delayed toxicities.

3. Clinical Endpoints and Surrogate Endpoints

Clinical endpoints directly measure patient outcomes such as survival, symptom improvement, or quality of life. In contrast, surrogate endpoint are measurable indicators that predict clinical benefit. Imaging-based surrogate endpoints, including changes in tumour size or organ function, can reduce trial duration and improve study efficiency when properly validated.

Limitations of Surrogate Endpoint

- Failure to predict true clinical outcomes
- May lead to false positive results

4. Imaging Biomarkers in Drug Development

Imaging biomarkers are objective indicators that reflect biological processes, of drug efficacy, facilitate patient stratification and support personalized treatment strategies. Common examples include tumour volume measurements, metabolic activity assessed by PET and functional MRI parameters.
An objectively measured characteristic indicating:

- Normal biological processes
- Disease processes
- Drug response

Role:

- Evaluate efficacy
- Evaluate safety
- Support dose selection
- Predict therapeutic response

5. Imaging in Pharmacokinetic (PK) Studies

Medical imaging plays an important role in pharmacokinetic (PK) studies by providing non-invasive methods to evaluate the absorption, distribution, metabolism and excretion (ADME) of drug in living organisms. Unlike conventional PK studies that primarily rely on plasma drug concentrations, imaging techniques enable direct visualization of drug localization and movement within target tissues. Commonly used imaging modalities include positron emission tomography (PET), mass spectrometry imaging (MSI) and optical fluorescence imaging. These approaches provide valuable information on tissue-specific drug exposure and improve the understanding of drug behaviour in vivo.

5.1 Positron Emission Tomography (PET) in Pharmacokinetics

Among available imaging modalities, PET is one of the most sensitive techniques for evaluating drug pharmacokinetics and molecular interactions during early clinical development. PET enables researchers to monitor drug distribution, tissue uptake, receptor binding and pharmacodynamic responses in real time. The technique also supports microdosing studies, in which radiolabelled compounds are administered at extremely low, non-pharmacological doses to supports microdosing studies, in which radiolabelled compounds are administered at extremely low, non-pharmacological doses to evaluate human pharmacokinetics before conventional phase 1 clinical trials. This approach reduces development risks while providing valuable information on drug disposition and target engagement.

Applications of PET in Drug Development

PET imaging has been successfully applied to a wide range of therapeutic agents, including anticancer drugs, anti-infective agents, and receptor-targeted therapies, In some cases, radiolabelled drugs are used to measure tissue concentrations and evaluate whether therapeutic levels are achieved at the disease site. In other cases, PET assesses receptor occupancy, binding affinity, and biological activity to determine the optimal therapeutic dose. These applications help researchers establish effective dosing regimens and improve confidence in clinical decision-making during drug development.

5.2 Magnetic Resonance Imaging (MRI)

MRI is highly effective for soft tissue visualization, making it ideal for continuous disease monitoring and evaluating how well a patient is responding to a drug.

5.3 Computed Tomography (CT)

CT scans are the gold standard for solid tumour assessment in oncology trials, providing clear structural data for drug response evaluation.

5.4 Single Photon Emission Computed Tomography (SPECT)

5.5 Ultrasound Imaging

5.6 Optical and Molecular Imaging

Examples of PK Imaging

Several drugs have demonstrated the value of PET imaging in pharmacokinetic evaluation. Radiolabelled fluconazole was used to determine drug concentrations in infected tissues and confirmed that adequate therapeutic levels were achieved at target sites. Similarly, PET imaging was employed during the development of aprepitant, a neurokinin-1 (NK-1) Receptor antagonist, to assess receptor occupancy within the brain. By measuring the displacement of a radiolabelled ligand, researchers were able to quantify receptor binding and optimize the clinical dosing strategy.

Imaging in pharmacodynamics (PD) and Drug Efficacy

Pharmacodynamic (PD) imaging plays a vital role in evaluating how drugs interact with their biological targets and produce therapeutic effects in vivo. Unlike pharmacokinetic studies that focus on drug distribution, PD imaging measures target engagement, biological activity, and physiological responses following drug administration. Medical imaging plays a important role in evaluating the pharmacodynamic effects and therapeutic efficacy of new drugs during clinical development. Imaging biomarkers and surrogate endpoints provide faster, more objective, and reliable information then traditional clinical endpoints such as mortality and morbidity, which often require long follow-up periods and large study populations. Advanced imaging techniques can detect small changes in disease progression or treatment response that may not be identified through conventional clinical assessments. This allows researchers to evaluate drug effectiveness at an earlier stage, improve statistical accuracy, and reduce the size and duration of clinical trials.

In oncology research, imaging is widely used to measure tumour size, blood flow, metabolism, and vascular changes as indicators of treatment response. For example, computed tomography (CT) imaging showed a significant reduction in tumour blood flow and blood volume shortly after treatment with bevacizumab, indicating an early therapeutic response. Similarly, FDG-PET imaging demonstrated that patients treated with imatinib showed reduced tumour glucose metabolism several weeks before changes become visible on CT scans. These finding suggest that functional imaging techniques can detect treatment response earlier than conventional imaging methods, enabling timely clinical decision.

Medical imaging is also valuable in evaluating drugs for non- cancer diseases. In patients with rheumatoid arthritis, radiographic imaging was used to assess joint damage during treatment with etanercept. Although conventional clinical assessments showed only limited differences between etanercept and standard therapy, imaging demonstrated a significant reduction in joint erosion and structural damage. This imaging findings provided strong evidence of the drug's effectiveness and supported its regulatory approval. Overall, pharmacodynamic imaging improves the assessment of drug efficacy, supports evidence-based clinical decision-making, and accelerates the development of safe and effective therapies.

Imaging in Drug Safety Assessment

Importance

Medical imaging plays a major role in monitoring drug safety during both preclinical trials. It helps detect organ toxicity even when laboratory tests appear normal. Medical imaging has become an important tool for assessing the safety of new drugs during both preclinical and clinical development. While

histopathological examination remains the standard method for evaluating tissue damage in preclinical studies, imaging techniques provide a non-invasive approach to detect structural and functional changes in different organs. During clinical trails, imaging is often the most effective method for identifying drug-induced toxicity because routine blood and urine test may remain normal despite the presence of early organ damage. Imaging allows researchers to visualize tissue-specific abnormalities and monitor organ function more accurately than conventional laboratory tests.

One of the major applications of imaging in the evaluation of drug-induced liver toxicity (hepatotoxicity). Advanced imaging techniques such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) can accurately measure liver fat content and identify abnormalities such as hepatic steatosis, glycogen accumulation, hepatocyte necrosis, and cholestasis. These imaging methods are particularly valuable because liver injury may occur even when serum liver enzyme levels are within the normal range. Early detection through imaging helps prevent severe complication such as acute liver failure, lactic acidosis, and other life-threatening conditions.

Medical imaging is equally important in monitoring drug-induced cardiotoxicity. Since the heart has a limited ability to regenerate damaged tissue, early detection of cardiac injury is essential. Although electrocardiography (ECG) is routinely used to monitor the electrical activity of the heart, it may not detect early structural damage. Echocardiography is widely used because it provides real-time, non-invasive, and cost-effective assessment of cardiac wall thickness, chamber size, ventricular function, and cardiac output. In addition, cardiac magnetic resonance imaging (cardiac MRI) offers detailed evaluation of myocardial structure, ventricular volumes, stroke volume, ejection fraction, making it highly useful for detecting early drug-induced cardiac abnormalities.

Advantages of Imaging in Drug Safety

- Detects structural and functional organ damage early.
- Provides organ-specific information.
- Identifies toxicity before symptoms appear.
- Complements laboratory biomarkers.
- Supports long-term safety monitoring.

Quantitative image processing and image data collection

A qualitative radiological approach to drug development needs to be converted into a quantitative biomarker or surrogate endpoint that may be used to make decisions. tumour volume, mean tumour permeability (ml min−1 100g−1), and FDG PET SUV are examples of parameters that describe the disease baseline and subsequent response to treatment. Patients must be able to compare the parameter, and the necessary data processing must be as objective as possible. For multicentre studies, image acquisition procedures should be standardized (as much as possible) throughout centres, and the study protocol should include the precise methods for storing, processing, and evaluating images. It is necessary to evaluate whether the manufacturer, model, and software version of the scanner will have an effect on variability. To guarantee data quality and protocol compliance across locations, it is preferable to collect pilot data before beginning clinical drug research. Additionally, some quality assurance procedures (e.g., scanner calibration for cross-site FDG-PET SUV measurements or MRI phantom measures of geometric homogeneity) can be necessary at the beginning and during the investigation. There are published consensus publications on how to do DCEMRI and analyse the data from several investigations.

Image process in plays a crucial role in clinical trials by providing accurate and objective analysis of medical images. The primary objective of image processing is to extract quantitative information from selected regions of interest (ROI) through tissue segmentation and computerized image analysis. The measurements help researchers assess disease severity, monitor treatment response, and evaluate the effectiveness of new drugs. Standardized imaging processing techniques improve the reliability and reproducibility of clinical trial data.

Whenever possible, clinical trials should use objectives and quantitative imaging end points rather than subjective assessments. Well-designed image evaluation forms and standardized reporting system

ensure accurate data collection while minimizing bias. Overall, proper image processing, secure data handling, and blinded image evaluation improve the quality, reliability, and scientific validity of imaging data, thereby supporting better assessment of the safety and efficacy of new drugs during clinical development. Ensuring the security of medical imaging data is essential to protect patient confidentiality and maintain the accuracy and reliability of clinical trial data. Imaging information should be transferred securely while preserving study blinding to prevent bias during data evaluation. Image analysis systems should include strong electronic security measures and comprehensive audit trails to monitor all user activities.

Although the original medical images must remain unchanged, image analysis such as measurements, annotations, and segmentations may be created, edited, or removed by authorized users. Therefore, secure computer-generated audit trails are necessary to record every action, including the date, time, user identity, and type of modification. These records should preserve previous information without overwriting or deleting it, ensuring complete data traceability, regulatory compliance, and the integrity of imaging data throughout the clinical trial process.

Advantages of Medical Imaging in Drug Development

- Early assessment of efficacy
- Identification of responders
- Objective biomarkers
- Pharmacokinetic evaluation
- Drug safety monitoring
- Reduced trial duration
- Smaller sample size
- Improved decision-making
- Improved statistical power
- Early identification of ineffective drug

Challenges

- Validation of imaging biomarkers
- High cost
- Standardization across study sites
- Inter-reader variability
- Regulatory acceptance
- Data security

Conclusion

Medical imaging as become an essential part of new drug clinical development. Modern imaging techniques, especially nuclear imaging methods such as PET, provide non-invasive and early assessment of drug activity in the human body. These techniques help researchers understand the pharmacokinetic and pharmacodynamic properties of new drugs.

During phase 1 and phase 2 clinical trials, imaging biomarkers support conventional clinical endpoints by providing early evidence of drug efficacy and helping researchers understand the drugs mechanism of action. In phase 3 studies, imaging findings provide reliable evidence the supports regulatory approval and improves confidence in the effectiveness of new therapies.

Medical imaging also plays an important role in monitoring drug safety by detecting organ toxicity and treatment-related changes at an early stage. With continuous advancements in imaging technology, software, and imaging tracers, the use of medical imaging in drug development is expected to expand further, leading to safer, more effective, and innovative medicines in the future.

References (selected)

1. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov. 2003; 2:123-31. Doi: 10.1038/nrd1007. (DOI) (PubMed) (Google Scholar).
2. Wang, Y-X., & Deng, M. (2010). Medical imaging in new drug clinical development. Journal of Thoracic Disease, 2(4), 245-252. https://doi.org/10.3978/j.issn.2072-1439.2010.11.10
3. Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework**. Clinical Pharmacology & therapeutics, 69(3), 89-95.**
4. U.S Food and Drug Administration (FDA). (2023). Biomarker Qualification Program. U.S.FDA. https://www.fda.gov./drugs/biomarkers-qualification-program
5. European Medicines Agency (EMA) (2022). Guidelines on the evaluation of anticancer medical products in man. European Medical Agency. https://www.ema.europa.eu/en/documents/scientific-gideline/guideline-evaluation-anticancer-medicinal-products-man-revision-5-en.pdf
6. James, M.L., & Gambhir, S.S. (2012). A molecular imaging primer: Modalities, imaging agents, and applications**. Physiological Reviews, 92(2), 897-965.**
7. Weber, W.A. (2009). Assessing tumour response to therapy**. Journal of Nuclear Medicine, 50(Suppl. 1), 1S-1OS.**
8. Sullivan, D. C., & Obuchowski, N.A. (2015). Imaging Biomarkers Alliance (QIBA): Improving Biomarkers in clinical trials**. Radiology**.
9. O'Connor, J. P. B., et al. (2017). Imaging biomarker roadmap for cancer studies**. Nature Review Clinical Oncology, 14(3), 169-186**.
10. Padhani, A. R., & Miles, K. A. (2010). Multiparametric imaging of tumour response to therapy**. Radiology.**
11. Wahl, R. L., et al. (2009). From RECIST to PERCIST: Evolving PET response criteria in solid tumours. **Journal of Nuclear Medicine, 50(Suppl. 1), 122S-150S.**